- Home
- ASMB vs RDCM Comparison
ASMB vs RDCM Comparison
Compare ASMB & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- RDCM
- Stock Information
- Founded
- ASMB 2005
- RDCM 1985
- Country
- ASMB United States
- RDCM Israel
- Employees
- ASMB N/A
- RDCM N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- ASMB Health Care
- RDCM Technology
- Exchange
- ASMB Nasdaq
- RDCM Nasdaq
- Market Cap
- ASMB 196.9M
- RDCM 203.7M
- IPO Year
- ASMB 2010
- RDCM 1997
- Fundamental
- Price
- ASMB $27.47
- RDCM $13.95
- Analyst Decision
- ASMB Strong Buy
- RDCM Strong Buy
- Analyst Count
- ASMB 4
- RDCM 1
- Target Price
- ASMB $42.33
- RDCM $18.00
- AVG Volume (30 Days)
- ASMB 156.9K
- RDCM 56.8K
- Earning Date
- ASMB 11-06-2025
- RDCM 11-12-2025
- Dividend Yield
- ASMB N/A
- RDCM N/A
- EPS Growth
- ASMB N/A
- RDCM 79.61
- EPS
- ASMB N/A
- RDCM 0.56
- Revenue
- ASMB $33,247,000.00
- RDCM $66,334,000.00
- Revenue This Year
- ASMB $14.32
- RDCM $18.07
- Revenue Next Year
- ASMB N/A
- RDCM $11.52
- P/E Ratio
- ASMB N/A
- RDCM $25.42
- Revenue Growth
- ASMB 54.77
- RDCM 18.18
- 52 Week Low
- ASMB $7.75
- RDCM $9.81
- 52 Week High
- ASMB $27.90
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- ASMB 65.33
- RDCM 48.99
- Support Level
- ASMB $23.21
- RDCM $13.76
- Resistance Level
- ASMB $27.17
- RDCM $14.88
- Average True Range (ATR)
- ASMB 1.70
- RDCM 0.58
- MACD
- ASMB 0.29
- RDCM -0.06
- Stochastic Oscillator
- ASMB 97.82
- RDCM 20.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.